Patent intelligence · US
US 11578371
Biomarkers for predicting tumor response to and toxicity of immunotherapy
Biomarkers for predicting tumor response to and toxicity of immunotherapy
Patent details — US 11578371
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 14, 2023
- Expiration
- Feb 9, 2043
- Applicant
- MIRA DX, INC.
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K39/00, A61P
Quick answer
US 11578371 (Biomarkers for predicting tumor response to and toxicity of immunotherapy) is held by MIRA DX, INC.. Status: granted. Granted Feb 14, 2023. Expires Feb 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MIRA DX, INC.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K39/00, A61P, A61P35/00
More from MIRA DX, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 11578371?
US 11578371 (Biomarkers for predicting tumor response to and toxicity of immunotherapy) is held by MIRA DX, INC.. Status: granted. Granted Feb 14, 2023. Expires Feb 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11578371?
MIRA DX, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 11578371 expire?
Our index shows an expiration date of Feb 9, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.